Drug Profile
XOMA 213
Alternative Names: LFA102; X 213; XOMA-213Latest Information Update: 08 Mar 2023
Price :
$50
*
At a glance
- Originator XOMA
- Developer Novartis; XOMA
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Prolactin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Breast cancer; Hyperprolactinaemia; Prostate cancer